<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001154</url>
  </required_header>
  <id_info>
    <org_study_id>760051</org_study_id>
    <secondary_id>76-H-0051</secondary_id>
    <nct_id>NCT00001154</nct_id>
  </id_info>
  <brief_title>Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins</brief_title>
  <official_title>Lipoprotein Metabolism in Normal Volunteers and Hyperlipoproteinemic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Researchers plan to study the fat-rich particles, called lipoproteins, which circulate in the&#xD;
      blood. This study is designed to improve understanding of normal, as well as abnormal,&#xD;
      lipoprotein metabolism and the role it plays in the development of hardening of the arteries&#xD;
      (atherosclerosis).&#xD;
&#xD;
      Patients participating in this study will receive injections of lipoproteins or&#xD;
      apolipoproteins (the protein component of lipoproteins) that have been isolated and purified.&#xD;
      These lipoproteins will be labeled with small amounts of radioactive material and sterilized&#xD;
      before they are injected into the patient.&#xD;
&#xD;
      Patients participating in the study will be required to have blood samples taken, and provide&#xD;
      urine samples throughout the course of the study. In addition, patient will be required to&#xD;
      follow a specially formulated diet. Patients will be weighed throughout the course of the&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose to investigate human in vivo lipoprotein metabolism using radiolabeled&#xD;
      apolipoproteins on plasma lipoproteins. Paired kinetic studies using dual-labeled iodinated&#xD;
      lipoproteins and apolipoproteins are performed in healthy volunteer controls with normal&#xD;
      lipids and subjects with dyslipidemia under controlled metabolic conditions. Studies are&#xD;
      designed to formulate metabolic pathways in patients with undefined genetic disorders of&#xD;
      lipid metabolism as well as in healthy volunteers to provide original insights into normal&#xD;
      and pathologic metabolic pathways. All kinetic data is computer analyzed to provide&#xD;
      quantitative data and facilitate direct comparison of multiple studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 3, 1976</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>No outcome. This is a disease discover protocol.</measure>
    <time_frame>5 years</time_frame>
    <description>Dyslipidemia</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">759</enrollment>
  <condition>Hypolipoproteinemia</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Dyslipidemia</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Subjects with new and undefined dyslipidemia</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Dsylipidemia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Subjects with new and undefined dyslipidemia-particularly familial disorders with extreme&#xD;
        phenotypes.&#xD;
&#xD;
        Healthy normal volunteers - (18 years old or older) controls to investigate the formation&#xD;
        of HDL for prebeta HDL.&#xD;
&#xD;
        Euthyroid.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Healthy control volunteers are initially screened for secondary causes of hyperlipidemia&#xD;
        and are excluded if they have any clinically significant laboratory abnormality (i.e.,&#xD;
        liver disease, disease, kidney disease, endocrine disease,), chronic medical problems&#xD;
        (i.e., hypertension, migraines, inflammatory bowel, hepatitis, HIV) or require any chronic&#xD;
        medications (i.e., acne, asthma).&#xD;
&#xD;
        The healthy control volunteers weight must fall within the current guidelines for ideal&#xD;
        body weight.&#xD;
&#xD;
        Pregnant women.&#xD;
&#xD;
        Unwilling to follow metabolic diet.&#xD;
&#xD;
        Allergic to iodine.&#xD;
&#xD;
        Unable to sign consent form.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert D Shamburek, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_1976-H-0051.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <verification_date>August 30, 2022</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>November 3, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 1999</study_first_posted>
  <last_update_submitted>January 20, 2023</last_update_submitted>
  <last_update_submitted_qc>January 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metabolism</keyword>
  <keyword>HDL</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>LDL</keyword>
  <keyword>Hypoalphalipoproteinemia</keyword>
  <keyword>Natural History</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypolipoproteinemias</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

